Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Chronic kidney disease is not uncommon among patients with PsA, with risk factors including diabetes and NSAID use, while ...

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Reports Q1 revenue $18.9M, consensus $18.8M. “We are off to a strong start to fiscal 2025 with total revenue increasing by 31% in the first ...

Introduction: The relationship between the phenotype and treatment of psoriatic arthritis (PsA) and the increased prevalence of cardiovascular comorbidities is not well studied. Objective: To assess ...

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...